Primo Capital launches €40M Primo Biotech Lazio fund with first close
Primo Capital launches Primo Biotech Lazio, a €40M-target biotech venture fund, with a first close anchored by Lazio Innova and Fondazione ENPAM.
Primo Capital launches Primo Biotech Lazio, a €40M-target biotech venture fund, with a first close anchored by Lazio Innova and Fondazione ENPAM.
Primo Capital has launched Primo Biotech Lazio, a venture capital fund for biotech with a €40 million target. The first close is complete, with Lazio Innova as cornerstone investor through the LAZIO Venture 2 fund of funds, which committed €17.5 million, and Fondazione ENPAM.
Letizia Goretti and Michele Cerqua are general partners, with Prof. Sergio Abrignani as scientific advisor. The fund will build a concentrated portfolio, mostly as lead investor, in biotech, advanced therapies and adjacent areas such as smart biomaterials and advanced biomedical devices. Oncology, rare diseases, neurology, immunology and regenerative medicine are among the focus areas, with a maximum of €12 million per company.
Led by CEO Antonio Concolino, Primo Capital manages more than €500 million across digital, health, climate and space funds, and is strengthening its presence in Rome with a permanent base.